• 1. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 5. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064

Introduction to 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol (CAS No. 1862993-64-3)

3-Methyl-4-(4-methylcyclohexyl)butan-2-ol, identified by its Chemical Abstracts Service (CAS) number 1862993-64-3, is a compound of significant interest in the field of organic chemistry and pharmaceutical research. This molecule, characterized by its complex alkyl and cycloalkyl substituents, has garnered attention due to its structural uniqueness and potential applications in synthetic chemistry and drug development. The presence of both a secondary alcohol functional group and a bulky 4-methylcyclohexyl side chain makes this compound a versatile intermediate for various chemical transformations.

The structural framework of 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol consists of a four-carbon backbone with a hydroxyl group at the second carbon position, flanked by a methyl group and a cyclohexyl ring substituted with another methyl group at the fourth carbon. This arrangement imparts distinct stereochemical properties to the molecule, which are critical for its reactivity and potential biological activity. The cyclohexyl moiety, in particular, introduces conformational flexibility, influencing both the compound's solubility and its interactions with biological targets.

In recent years, the pharmaceutical industry has shown increasing interest in designing molecules with complex cyclic structures, as these often exhibit improved pharmacokinetic profiles and enhanced binding affinity to biological receptors. 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol fits well within this trend, offering a scaffold that can be modified to explore novel therapeutic avenues. Its alcohol functionality provides a site for further derivatization, allowing chemists to introduce additional pharmacophores or improve metabolic stability.

One of the most compelling aspects of 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol is its potential role as a building block in the synthesis of more complex molecules. The combination of a linear aliphatic chain with a bulky cyclic substituent creates a balance between rigidity and flexibility, which is often desirable in drug candidates. This balance can influence how the molecule interacts with enzymes or receptors in vitro and in vivo, potentially leading to improved efficacy or reduced side effects.

Recent studies have begun to explore the reactivity of 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol under various conditions, highlighting its utility in synthetic chemistry. For instance, researchers have investigated its participation in nucleophilic addition reactions, where the alcohol group can serve as an acceptor for electrophiles. Additionally, the compound's ability to undergo oxidation or reduction reactions offers further possibilities for functionalization. These chemical properties make it a valuable asset in medicinal chemistry libraries, where such intermediates are often used to generate analogs with tailored properties.

The stereochemistry of 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol is another area of active investigation. The presence of multiple chiral centers allows for the synthesis of enantiomerically pure forms, which can exhibit markedly different biological activities. This aspect is particularly relevant in drug development, where enantiomeric purity can significantly impact a molecule's therapeutic profile. Techniques such as asymmetric synthesis or chiral resolution are being explored to isolate specific stereoisomers for further study.

In the context of drug discovery, 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol has been used as a starting material for exploring new chemical entities (NCEs). Its structural features suggest potential applications in areas such as central nervous system (CNS) drug development, where bulky substituents can enhance blood-brain barrier penetration. Furthermore, its alcohol functionality makes it amenable to derivatization into esters or ethers, which are common motifs in bioactive molecules.

The synthesis of 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol itself presents an interesting challenge due to its complex structure. Traditional synthetic routes may involve multi-step sequences that require careful optimization to achieve high yields and purity. Advances in catalytic methods have also opened new avenues for constructing this molecule more efficiently. For example, transition metal-catalyzed reactions can be employed to form carbon-carbon bonds between the cyclohexyl and aliphatic chains with high selectivity.

As our understanding of molecular interactions continues to evolve, compounds like 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol will play an increasingly important role in shaping future therapies. Their unique structural features offer opportunities to address unmet medical needs by providing novel scaffolds for drug design. By leveraging their synthetic versatility and exploring their biological potential, researchers can unlock new possibilities in medicinal chemistry.

The future direction of research on 3-Methyl-4-(4-methylcyclohexyl)butan-2-ol may include expanding its applications into other areas beyond traditional pharmaceuticals. For instance, its use as a ligand in material science or as an intermediate in agrochemical synthesis could be explored. The compound's ability to participate in diverse chemical transformations makes it a promising candidate for interdisciplinary studies.

In conclusion,3-Methyl-4-(4-methylcyclohexyl)butan-2-ol (CAS No. 1862993-64-3) is a multifaceted compound with significant potential in both academic research and industrial applications. Its unique structure provides chemists with a rich palette for synthetic innovation, while its functional groups offer opportunities for biological exploration. As research continues to uncover new uses for this molecule,3-Methyl-*(-(methylene)-*(methylene)-*(methylene)-*(*methylene*)*]-*(*methylene*)*)-*(*isopropylidene*)*)-*methanol*, it is poised to make meaningful contributions to the advancement of chemical science and drug discovery.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)